x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

Global Regions ( XML Feed )
United States ( XML Feed )

Sep 30, 2015 12:22 EST

Celleritas Bioscience – Our technology accelerates big pharma research

iCrowdNewswire - Sep 30, 2015
 
 
 

In the biotech world, innovation is like breathing.  It must happen naturally, or you won’t survive.

We’ve developed a proprietary solution called Celleritas Light Technology, or CLT, that saves the big boys big money on R&D.  More importantly, our process gets the drugs developed quicker, and with greater success – making life saving therapies more readily available to those in need.

With so many blockbuster drugs losing patent protection in the next 5 years, the big players will be lining up to utilize our CLT process – and we won’t stop until it’s perfected.

 
 
 
 

There’s a new generation of pharmaceutical research upon us.  The days of utilizing strictly chemical-based processes to manufacture drugs are over.  Today, biologic drugs are becoming more and more important, especially in the treatment of advanced or aggresive diseases such as cancer, HIV and arthritis. These drugs rely on genetically modified cellular organisms to produce them in a biological process (using recombinant DNA technology).

These increasingly complex manufacturing methods have the big pharma competitive landscape seriously heating up. 

Quite often, the organism’s energy content becomes depleted when used in biologic production methods and the efforts as a whole to produce a new drug prove ineffective.  The result: the cost of new biologic drugs has been pushed to astronomical highs, as the few successful efforts must recover the high R&D costs incurred across the many failures.

There’s an intellectual property issue, too.  Of the top 8 blockbuster biologic drugs on the market today, 7 of them are approaching the “patent cliff” – and will lose their market exclusivity protection by the year 2020.  Drug producers are lining up with competitor products. With big changes coming soon, there’s a race to corner the market on a biotech solution that will accelerate the next generation of blockbuster drugs.

 
 
 
 

We’re here for you, big pharma.

At Celleritas Bioscience, we’ve developed a light-based approach to biologic drug development called Celleritas Light Technology, or CLT.  CLT is genetically engineered into the cellular organisms used to produce biologic drugs.  With methods vastly simpler and more efficient than standard cellular metabolism, CLT converts any source of light into chemical energy that is used by the oragnism – and does it in a single step. 

In doing so, it super charges the organism, overcoming many of the cellular bottlenecks that inhibit successful drug development.

CLT isn’t just spearheading the successful development of the next generation of blockbuster drugs…it’s also bending the cost curve.  Manufacturers using our process can save significant amounts of money, time, and error associated with current production methods.  With efficient use of R&D resources being more important than ever, incorporating CLT is the best thing you can do to stay competitive.

Our proprietary, innovative biotech solution increases the productivity of cellular organisms used to produce drugs.  It can be deployed in the manufacturing of anybiologic, yet does not interfere with the drug itself.

 
 
 
 

The CLT process is complex – but here’s how it works, in a nutshell:

This excess energy production enables the organism in question to perform existing tasks at greater efficiency, as well as perform additional tasks, such as cellular maintenance and protein refolding of complex and specialized biologic drugs.  The result: massively increased output of bioactive molecules of the drug – leading to more efficient production and a greater output of usable product.

CLT is a groundbreaking biotechnology process with seemingly endless possible applications.  Here are some of its more impressive features that help provide such wide-reaching benefits:

 CLT can be easily integrated into a range of cellular organisms, delivering value for end products across a variety of industries.

  CLT allows for a shorter production cycle, increased productive capacity, and higher yields – resulting in increased output and a more efficient manufacturing process.

  CLT doesn’t alter any of the organism’s biologically fundamental properties; therefore, the upgraded organism can be used as a “drop-in” product in its existing industrial applications.

  CLT bypasses existing cellular metabolic pathways that interfere with the organism’s productivity, resulting in faster and higher levels of energy production/productivity.

  From infrared to UV to sunlight, CLT can utilize a variety of different natural and artificial light spectrums as its energy source – and can be customized to respond to a wide variety of wavelengths.

  Customers can drastically reduce carbon dioxide emissions using CLT, and reap the financial value generated from these carbon offset credits.

 
 
 
 

It’s early, but we’re underway at Celleritas Bioscience – and on the way to fulfilling our vision.  Currently, we’re in the initial proof of concept stage.  All patent applications have been submitted and are pending, which is a huge and extremely vital step in our development.  This IP is a hugely valuable asset as it protects our process and makes it unique to Celleritas Bioscience.

We’ve had several successful meetings with US and European pharma companies and have garnered very positive feedback regarding the use of our technology, including successfully executing a Technology Evaluation Agreement with a top-10 global pharma firm.  We’ve secured key partnerships: with the Aaron Diamond AIDS Research Center, Harlem Biospace, and the University of Maryland’s Bioprocess Scale-Up Center.  The ADARC will provide us with genetic material for their biologic drug candidates under development to treat HIV, we will use the Harlem Biospace lab facility to complete our proof of concept, and will use the Bioprocess Scale-Up Center to demonstrate the commercial performance of our technology.

           

For more on what’s next for Celleritas Bioscience, and where we’re ultimately headed, please request access to the Business Plan portion of our Fundable profile!

 
 
 
 

Meet us, Fundable!  We’re Rahul and Matthew, two forward-thinking, results-driven business leaders tasked with leading World Biotechnology.  From the first moment we envisioned CLT, we were taken aback and floored by its amazing potential – and now we’re united under Celleritas Bioscience’s vision.  Here’s a little more about us:

Rahul Parmar, CEO
Mr. Parmar is an entrepreneur who also has 10 plus years’ experience in investment banking in New York and London.  His expertise lies in capital raising, financial contract negotiation, and treasury analysis.  Uninspired by spending long hours helping financiers increase their already mammoth profits, he decided to do something a little more fulfilling and co-founded Celleritas Bioscience.  As CEO, Mr. Parmar is responsible for securing funding, personnel, and strategic direction.

Matthew McNatt PhD., CTO
Dr. McNatt has over 15 years’ research experience investigating a variety of cell cultures.  His scientific expertise is in biochemistry, virology, and molecular and cell biology.  He eventually ended up in NYC to begin his postdoctoral career in a top tier HIV-1 lab, where he learned how to manipulate mammalian cell lines and viruses. Dr. McNatt co-founded Celleritas Bioscience to pursue his dream of entrepreneurial science.  As CTO, Dr. McNatt is responsible for development of technology and IP, identifying R&D priorities, and executing the operational plan.

Board of Advisors
We’re backed by an impressive trio of business and biotech minds.  They includeDavid D. Ho (1996 Time Magazine Man of the Year), Jeffrey Hwang (COO of IRX Therapeutics), and Sam Kongsamut (experienced pharma external innovation specialist).  The wealth of knowledge that these three gentlemen offer, specifically in the biotech space, cannot be understated.

Contact Information:

Rahul Parmar
Matthew McNatt PhD.

View Related News >
support